RetinalGenix Technologies (RTGN) Shares Outstanding (Diluted Average) (2022 - 2026)
RetinalGenix Technologies' (RTGN) quarterly Shares Outstanding (Diluted Average) came in at $18.8 million in Q1 2026, up 1.25% year-on-year from $18.5 million in Q1 2025, and up 1.04% quarter-over-quarter from $18.6 million in Q4 2025.
RetinalGenix Technologies (RTGN) Shares Outstanding (Diluted Average) (2022 - 2026) Analysis & Trends
RetinalGenix Technologies has disclosed Shares Outstanding (Diluted Average) across 5 years of filings, most recently posting $18.8 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $18.8 million, up 1.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.8 million (up 1.25% YoY), and the FY2025 annual result was $18.6 million, up 3.47% from the prior year.
- Shares Outstanding (Diluted Average) came in at $18.8 million for Q1 2026 at RetinalGenix Technologies, up from $18.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $18.8 million in Q1 2026 to a low of $14.4 million in Q2 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $17.8 million (2024), against an average of $17.4 million.
- Across the five-year window, Shares Outstanding (Diluted Average) gained 19.94% in 2023 and increased 1.25% in 2026, its largest moves.
- RetinalGenix Technologies' Shares Outstanding (Diluted Average) stood at $15.6 million in 2022, then grew by 11.34% to $17.4 million in 2023, then gained by 3.39% to $17.9 million in 2024, then gained by 3.47% to $18.6 million in 2025, then climbed by 1.04% to $18.8 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $18.8 million (Q1 2026), $18.6 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.75 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 386.50 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.29 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.50 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 580.70 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 457.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 393.60 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | RetinalGenix Technologies | - | - | - | 18.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.75 Mn |
| Dec 31, 2025 | 18.56 Mn |
| Sep 30, 2025 | 18.54 Mn |
| Jun 30, 2025 | 18.53 Mn |
| Mar 31, 2025 | 18.52 Mn |
| Dec 31, 2024 | 17.94 Mn |
| Sep 30, 2024 | 17.87 Mn |
| Jun 30, 2024 | 17.86 Mn |
| Mar 31, 2024 | 17.67 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Sep 30, 2023 | 17.27 Mn |
| Jun 30, 2023 | 17.27 Mn |
| Mar 31, 2023 | 17.27 Mn |
| Dec 31, 2022 | 15.58 Mn |
| Sep 30, 2022 | 15.13 Mn |
| Jun 30, 2022 | 14.40 Mn |